Back to Authors

Gheorghiade, Mihai

0000-0003-3115-7433

Mayo Clinic

Northwestern University

Citations 4

Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction
Fridman, Yaron, Daya, Hussein Abu , Piehler, Kayla, Kadakkal, Ajay, Miller, Chris , Ugander, Martin , Maanja, Maren , Shah, Dipan J. , Simon, Marc A. , Senni, Michele , Butler, Javed , Dı́ez, Javier , Redfield, Margaret M. , Gheorghiade, Mihai , Schelbert, Erik B. , Wong, Timothy C. , Kellman, Peter , Abebe, Kaleab Z , Quarta, Giovanni , Senni, Michele

JAMA Cardiology | August 2, 2017 | Volume: 2 | Issue: 9 | Pages: 995

10.1001/jamacardio.2017.2511 Get It

The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
Greene, Stephen J. , Gheorghiade, Mihai , Pieske, Burkert , Burnett, John C. , Roessig, Lothar, Stasch, Johannes‐Peter, Solomon, Scott D. , Paulus, Walter J. , Borlaug, Barry A. , Vaduganathan, Muthiah , Solomon, Scott David , Butler, Javed

Journal of the American Heart Association | December 12, 2013 | Volume: 2 | Issue: 6 | Pages: No page available

10.1161/jaha.113.000536 Get It

Left Ventricular Dysfunction With Pulmonary Hypertension
Kalogeropoulos, Andreas P. , Georgiopoulou, Vasiliki V., Gheorghiade, Mihai , Borlaug, Barry A. , Gheorghiade, Mihai , Butler, Javed

Circulation: Heart Failure | May 21, 2013 | Volume: 6 | Issue: 3 | Pages: 584-593

10.1161/circheartfailure.112.000096 Get It

Critical Elements of Clinical Follow-Up After Hospital Discharge for Heart Failure: Insights from the EVEREST Trial
Gheorghiade, Mihai , Hauptman, Paul J. , Zannad, Faı̈ez , Maggioni, Aldo P. , Konstam, Marvin A. , Spertus, John A. , Dunlay, Shannon M. , Reid, Kimberly J. , Allen, Larry A. , Chan, Paul S. , Swedberg, Karl B , Spertus, John A , Maggioni, Aldo P

European Journal of Heart Failure | March 2, 2010 | Volume: 12 | Issue: 4 | Pages: 367-374

10.1093/eurjhf/hfq019 Get It

Abstract Aims Hospitalized heart failure (HF) patients are at high risk for death and readmission. We examined the incremental value of data obtained 1 week after HF hospital discharge in predicting mortality and readmission. Methods and results In the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with tolvaptan, 1528 hospitalized patients (ejection fraction ≤40%) with a physical examination, laboratories, and health status [Kansas City Cardiomyopathy Questionnaire (KCCQ)] assessments 1 week after discharge were included. The ability to predict 1 year cardiovascular rehospitalization and mortality was assessed with Cox models, c-statistics, and the integrated discrimination improvement (IDI). Not using a beta-blocker, rales, pedal oedema, hyponatraemia, lower creatinine clearance, higher brain natriuretic peptide, and worse health status were independent risk factors for rehospitalization and death. The c-statistic for the base model (history and medications) was 0.657. The model improved with physical examination, laboratory, and KCCQ results, with IDI increases of 4.9, 7.0, and 3.2%, respectively (P < 0.001 each). The combination of all three offered the greatest incremental gain (c-statistic 0.749; IDI increase 10.8%). Conclusion Physical examination, laboratories, and KCCQ assessed 1 week after discharge offer important prognostic information, suggesting that all are critical components of outpatient evaluation after HF hospitalization.